Carmellose sodium with glycerol and hyaluronic acid
Brand: Optive Fusion
PBAC's latest decision on Carmellose sodium with glycerol and hyaluronic acid: Recommended with restriction (2023). Considered for Treatment of severe dry eye syndrome.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Patients with severe dry eye syndrome (including moderate to severe dry eye in the trial population).
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Change in Global Ocular Staining Score (GOSS) from baseline at day 35
Pivotal trial size
79 patients
Key trials
NCT02117687 (Labetoulle 2017)
Comparator
hyaluronate sodium 0.1%
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission did not provide cost-minimisation approach or equi-effective dose analysis.